Skip to main content

Advertisement

SpringerLink
Log in

Quality of life following prostate cancer treatments

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Quality of life is of major concern to patients when choosing a treatment for prostate cancer. Health-related quality of life (HRQOL) is a patient-centered variable from the field of health services research that can be assessed in a valid and reliable manner. Using standardized questionnaires specifically designed to measure HRQOL in men with prostate cancer, we can now study the effect of various treatments on patients’ quality of life. Treatments for metastatic prostate cancer can have significant effects in all areas of patients’ quality of life. Patients with localized disease undergoing radical prostatectomy (RP) tend to have more sexual and urinary dysfunction than do men undergoing external beam radiation therapy (EBRT), although both groups have worse quality of life in these areas than age-matched controls. Men undergoing EBRT have worse bowel function than age-matched controls or men undergoing RP. Recent studies of men undergoing interstitial brachytherapy indicate that these patients have less urinary leakage than those who undergo RP, but experience considerably more irritative voiding symptoms, which can profoundly affect quality of life. Patients need to be informed of the possible impact of therapy on quality of life when choosing treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Schellhammer P, Cockett A, Boccon-Gibod L, et al.: Assessment of endpoints for clinical trials for localized prostate cancer. Urology 1997, 49:27–38.

    Article  PubMed  CAS  Google Scholar 

  2. Patrick DL, Erickson P: Assessing health-related quality of life for clinical decision-making. In Quality of Life Assessment: Key issues in the 1990’s. Edited by Walker SR and Rosser RM. Dordrecht: Kluwer Academic Publishers; 1993:390–403.

    Google Scholar 

  3. Litwin MS, Lubeck DP, Henning JM, et al.: Differences in Urologist and Patients Assessments of Health Related Quality of Life in Men with Prostate Cancer: Results from the Capsure Database. J Urol 1998, 159:1988–1992.

    Article  PubMed  CAS  Google Scholar 

  4. Litwin MS, McGuigan KA: Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999, 17:2882–2888.

    PubMed  CAS  Google Scholar 

  5. Litwin MS, Hays RD, Fink A, et al.: The UCLA Prostate Cancer Index: development, reliability, and validity of a healthrelated quality of life measure. Med Care 1998, 36:1002–1012.

    Article  PubMed  CAS  Google Scholar 

  6. Aaronson NK, Ahmedzai S, Bergman B, et al.: The European Organization for Research and the treatment of Cancer QLQC30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:356–365.

    Article  Google Scholar 

  7. Borghede G, Karlsson J, Sullivan M: Quality of life in patients with prostatic cancer: results from a Swedish population study. J Urol 1997, 158:1477–1485.

    Article  PubMed  CAS  Google Scholar 

  8. Albertsen PC, Aaronson NK, Muller MJ, et al.: Health-related quality of life among patients with metastatic prostate cancer. Urology 1997, 49:207–216.

    Article  PubMed  CAS  Google Scholar 

  9. Esper P, Mo F, Chodak G, et al.: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997, 50:920–928.

    Article  PubMed  CAS  Google Scholar 

  10. Clark JA, Wray N, Brody B, et al.: Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997, 45:1299–1309.

    Article  PubMed  CAS  Google Scholar 

  11. The Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997, 79:235–246.

    Google Scholar 

  12. Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993, 71:1143–1150.

    Article  PubMed  CAS  Google Scholar 

  13. Litwin MS, Shpall AI, Dorey F, et al.: Quality-of-life outcomes in long-term survivors of advanced prostate cancer. Am J Clin Oncol 1998, 21:327–332. A longitudinal observational study of HRQOL in men with metastatic disease using a validated instrument. Patients were each followed for at last 1 year. Results demonstrate that there are no differences in general HRQOL outcomes between medical versus surgical castration.

    Article  PubMed  CAS  Google Scholar 

  14. Moinpour CM, Savage MJ, Troxel A, et al.: Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst 1998, 90:1537–1544. An important randomized clinical trial measuring the effect of total androgen blockade on patients’ quality of life. Patients randomized to orchiectomy and flutamide had significantly worse HRQOL outcomes than those who received orchiectomy and placebo. This study demonstrates that the addition of androgen blockade may have a deleterious effect on patients’ quality of life that may offset any possible increases in overall life expectancy.

    Article  PubMed  CAS  Google Scholar 

  15. Iversen P, Tyrrell CJ, Kaisary AV, et al.: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology 1998, 51:389–396.

    Article  PubMed  CAS  Google Scholar 

  16. Iversen P: Quality of life issues relating to endocrine treatment options. Eur Urol 1999, 36:20–26.

    Article  PubMed  Google Scholar 

  17. Schroder FH, Collette L, de Reijke TM, et al.: Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000, 82:283–290.

    Article  PubMed  CAS  Google Scholar 

  18. Curran D, Fossa S, Aaronson N, et al.: Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG). Eur J Cancer 1997, 33:1809–1814.

    Article  PubMed  CAS  Google Scholar 

  19. Kantoff PW, Halabi S, Conaway M, et al.: Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999, 17:2506–2513.

    PubMed  CAS  Google Scholar 

  20. Osoba D, Tannock IF, Ernst DS, et al.: Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654–1663.

    PubMed  CAS  Google Scholar 

  21. Stanford J, Feng Z, Hamilton A, et al.: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. JAMA 2000, 283:354–360. The first prospective, population-based study to examine quality of life outcomes following radical prostatectomy. 8% incontinence rate and 60% impotence rate likely represent the true incidence of these outcomes in community practice.

    Article  PubMed  CAS  Google Scholar 

  22. Steiner MS: Current results and patient selection for nervesparing radical retropubic prostatectomy. Semin Urol Oncol 1995, 13:204–214.

    PubMed  CAS  Google Scholar 

  23. Kao T, Cruess D, Garner D, et al.: Multicenter patient selfreporting questionnaire on impotence, incontinence and stricture after radical prostectomy. J Urol 2000, 163:858–864.

    Article  PubMed  CAS  Google Scholar 

  24. Murphy G, Mettlin C, Menck H, et al.: National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994, 152:1817–1819.

    PubMed  CAS  Google Scholar 

  25. Talcott JA, Rieker P, Clark JA, et al.: Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998, 16:275–283. A controversial study comparing disease-specific quality of life outcomes in men who received nerve-sparing versus non-nerve-sparing radical prostatectomy. The authors conclude that potency rates following the two techniques are comparable. Although this study has been criticized its single institution nature, it is still thoughtprovoking and serves as a reminder that further research is needed in the area.

    PubMed  CAS  Google Scholar 

  26. Litwin MS, Flanders SC, Pasta DJ, et al.: Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999, 54:503–508.

    Article  PubMed  CAS  Google Scholar 

  27. Lubeck DP, Litwin MS, Henning JM, et al.: Changes in healthrelated quality of life in the first year after treatment for prostate cancer: results from CaPSURE. Urology 1999, 53:180–186.

    Article  PubMed  CAS  Google Scholar 

  28. Clark JA, Rieker P, Propert KJ, et al.: Changes in quality of life following treatment for early prostate cancer. Urology 1999, 53:161–168.

    Article  PubMed  CAS  Google Scholar 

  29. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al.: Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995, 45:1007–1013.

    Article  PubMed  Google Scholar 

  30. Shrader-Bogen CL, Kjellberg JL, McPherson CP, et al.: Quality of life and treatment outcomes: prostate carcinoma patients’ perspectives after prostatectomy or radiation therapy. Cancer 1997, 79:1977–1986.

    Article  PubMed  CAS  Google Scholar 

  31. Herr HW: Quality of life of incontinent men after radical prostatectomy. J Urol 1994, 151:652–654.

    PubMed  CAS  Google Scholar 

  32. Litwin MS, McGuigan KA, Shpall AI, et al.: Recovery of health-related quality of life in the year after radical prostatectomy: Early experience. J Urol 1999, 161:515–519.

    Article  PubMed  CAS  Google Scholar 

  33. Penson D, Litwin M, Lubeck D, et al.: Transitions in healthrelated quality of life during the first nine months after diagnosis with prostate cancer. Prostate Cancer Prostatic Dis 1998, 1:134–143.

    Article  PubMed  Google Scholar 

  34. Dale W, Campbell T, Ignacio L, et al.: Self-assessed healthrelated quality of life in men being treated for prostate cancer with radiotherapy: instrument validation and its relation to patient-assessed bother of symptoms. Urology 1999, 53:359–366.

    Article  PubMed  CAS  Google Scholar 

  35. Litwin MS, Hays RD, Fink A, et al.: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995, 273:129–135.

    Article  PubMed  CAS  Google Scholar 

  36. Fransson P and Widmark A: Late side effects unchanged 4–8 years after radiotherapy for prostate carcinoma: a comparison with age-matched controls. Cancer 1999, 85:678–688. Case series of men undergoing EBRT with longest follow-up. Higher incidence of permanent side-effects than expected at 8 years after treatment.

    Article  PubMed  CAS  Google Scholar 

  37. Franklin CI, Parker CA, Morton KM: Late effects of radiation therapy for prostate carcinoma: the patient’s perspective of bladder, bowel and sexual morbidity. Australas Radiol 1998, 42:58–65.

    PubMed  CAS  Google Scholar 

  38. Reddy SM, Ruby J, Wallace M, et al.: Patient self-assessment of complications and quality of life after conformal neutron and photon irradiation for localized prostate cancer. Radiat Oncol Invest 1997, 5:252–256.

    Article  CAS  Google Scholar 

  39. Mantz CA, Nautiyal J, Awan A, et al.: Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am 1999, 5:230–236.

    PubMed  CAS  Google Scholar 

  40. Fowler FJ, Jr., Barry MJ, Lu-Yao G, et al.: Outcomes of externalbeam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology and end results areas. J Clin Oncol 1996, 14:2258–2265.

    PubMed  Google Scholar 

  41. Helgason AR, Fredrikson M, Adolfsson J, et al.: Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life. Int J Radiat Oncol Biol Phys 1995, 32:33–39.

    Article  PubMed  CAS  Google Scholar 

  42. Widmark A, Fransson P, Tavelin B: Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994, 74:2520–2532.

    Article  PubMed  CAS  Google Scholar 

  43. Crook J, Esche B, Futter N: Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient’s perspective. Urology 1996, 47:387–394.

    Article  PubMed  CAS  Google Scholar 

  44. Brandeis J, Litwin M, Burnison C, et al.: Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000, 163:851–857. Cross-sectional study directly comparing men undergoing surgery and brachytherapy to age-matched controls.

    Article  PubMed  CAS  Google Scholar 

  45. Joly F, Brune D, Couette JE, et al.: Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998, 9:751–757.

    Article  PubMed  CAS  Google Scholar 

  46. Arterbery VE, Frazier A, Dalmia P, et al.: Quality of life after permanent prostate implant. Semin Surg Oncol 1997, 13:461–464.

    Article  PubMed  CAS  Google Scholar 

  47. Lee WR, McQuellon RP, Case LD, et al.: Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol 1999, 162:403–406. A prospective study assessing quality of life prior to and three months after implantation of radioactive seeds. Although general HRQOL has returned to baseline at 3 months, significant irritative voiding symptoms persist which affect quality of life.

    Article  PubMed  CAS  Google Scholar 

  48. Akakura K, Isaka S, Akimoto S, et al.: Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999, 54:313–318.

    Article  PubMed  CAS  Google Scholar 

  49. Lim AJ, Brandon AH, Fiedler J, et al.: Quality of life: radical prostatectomy versus radiation therapy for prostate cancer. J Urol 1995, 154:1420–1425.

    Article  PubMed  CAS  Google Scholar 

  50. McCammon KA, Kolm P, Main B, et al.: Comparative qualityof-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer. Urology 1999, 54:509–516. A cross-sectional study comparing 203 men undergoing RP with 257 receiving EBRT. All HRQOL measurements were taken at least 1 year after therapy. Although the results are similar to other studies, the authors also compared physician assessment with patient self-report and found significant disparities.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Washington School of Medicine, VAPSHCS Section of Urology, 112-UR, 1660 South Columbian Way, 98108, Seattle, WA, USA

    David F. Penson MD

Authors
  1. David F. Penson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Penson, D.F. Quality of life following prostate cancer treatments. Curr Urol Rep 1, 71–77 (2000). https://doi.org/10.1007/s11934-000-0038-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-000-0038-9

Keywords

Search

Navigation